Prostate cancer (PC) is a common and multifocal disease, with symptoms ranging from harmless to lethal. In Sweden, about 10000 new cases are diagnosed every year.
Breast cancer, the most common cancer in women, needs improved drugs to increase patient survival. Our innovation, a small molecule that simultaneously affects two well-recognized cancer targets, the STAT3 protein and G-quadruplex (G4) DNA structures, will reduce drug-resistance and improve treatment.
MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.
By combining two different methods, Medsens AB is aiming at offering a whole new tool for realtime microdiagnostics during prostate cancer surgery. The company’s instrument is far more accurate that the methods used by clinicians today – which could make surginal procedures much more efficient. The project is based on the work of Olof Lindahl och Kerstin Ramser.
Our project goals aim at increased survival, improved quality of life and less suffering for cancer patients. Our novel chemical entities (NCE) can prevent over-activation of certain signaling pathways and are based on existing pharmaceuticals that are well tolerable and easy to produce. This will be a first in class drug with little side effects (known drug class), addressing cancer induced cachexia and suppression of the immune system.
Hiloprobe AB has developed a superior method of diagnosing and prognosing patients with colorectal cancer after surgery. Their innovative clinical tool – the ColoNode is far more accurate than current standard procedures, opening up the possibility of personalized medicine within the colorectal cancer field.